Victor Srougi

Victor Srougi

Auto-generated profile, based on publicly available information

Victor Srougi

Divisão de Urologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo , São Paulo 05403-000

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AMAna Alice W Maciel
Ana Alice W Maciel
TFThais C Freitas
Thais C Freitas
GFGustavo F C Fagundes
Gustavo F C Fagundes
JPJanaina Petenuci
Janaina Petenuci
LVLeticia A P Vilela
Leticia A P Vilela
Madson AlmeidaMadson Almeida
Madson Almeida
Context: Primary aldosteronism (PA) screening relies on an elevated aldosterone to renin ratio with a minimum aldosterone level, which varies from 10 to 15 ng/dL (277-415.5 pmol/L) using immunoassay.Objective: To evaluate intra-individual coefficient of variation (CV) of aldosterone and aldosterone to direct renin concentration ratio (A/DRC) and its impact on PA screening.Methods: A total of 671 aldosterone and DRC measurements were performed by the same chemiluminescence assays in a large cohort of 216 patients with confirmed PA and at least 2 screenings.Results: The median intra-individual CV of aldosterone and A/DRC was 26.8% and 26.7%. Almost 40% of the patients had at least one aldosterone level <15 ng/dL, 19.9% had at least 2 aldosterone levels <15 ng/dL, and 16.2% had mean aldosterone levels 2 ng/dL/µIU/mL had a true positive rate for PA diagnosis of 94.4% and 98.4% when based on 1 or 2 assessments, respectively. CV of aldosterone and A/DRC were not affected by sex, use of interfering antihypertensive medications, PA lateralization, hypokalemia, age, and number of hormone measurements.Conclusion: Aldosterone concentrations had a high CV in PA patients, which results in an elevated rate of false negatives in a single screening for PA. Therefore, PA screening should be based on at least 2 screenings with concomitant aldosterone and renin measurements.

1 April 2016 in Urology
Verified
Journal Article
Closed access
VSVictor Srougi
Victor Srougi
BRBruno A. Rocha
Bruno A. Rocha
FTFabio Y. Tanno
Fabio Y. Tanno
MAMadson Q. Almeida
Madson Q. Almeida
RBRonaldo H. Baroni
Ronaldo H. Baroni
JCJose L. Chambô
Jose L. Chambô

30 November 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
VSVictor Srougi
Victor Srougi
IBIrina Bancos
Irina Bancos
MDMarilyne Daher
Marilyne Daher
JLJeffrey E Lee
Jeffrey E Lee
PGPaul H Graham
Paul H Graham
MFMaria Candida B. V. Fragoso
Maria Candida B. V. Fragoso
Context: The role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood. Objective: To analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC. Design and Setting: We performed a multicentric, retrospective paired cohort study comparing the overall survival (OS) in patients with metastatic ACC who were treated either with cytoreductive surgery (CR group) or without cytoreductive surgery (no-CR group) of the primary tumor. Data were retrieved from 9 referral centers in the American-Australian-Asian Adrenal Alliance collaborative research group. Patients: Patients aged ≥18 years with metastatic ACC at initial presentation who were treated between January 1, 1995, and May 31, 2019. Intervention: Performance (or not) of cytoreductive surgery of the primary tumor. Main outcome and measures: A propensity score match was done using age and the number of organs with metastasis (≤2 or >2). The main outcome was OS, determined from the date of diagnosis until death or until last follow-up for living patients. Results: Of 339 patients pooled, 239 were paired and included: 128 in the CR group and 111 in the no-CR group. The mean follow-up was 67 months. Patients in the no-CR group had greater risk of death than did patients in the CR group (hazard ratio [HR] = 3.18; 95% CI, 2.34-4.32). Independent predictors of survival included age (HR = 1.02; 95% CI, 1.00-1.03), hormone excess (HR = 2.56; 95% CI, 1.66-3.92), and local metastasis therapy (HR = 0.41; 95% CI, 0.47-0.65). Conclusion: Cytoreductive surgery of the primary tumor in patients with metastatic ACC is associated with prolonged survival.

1 September 2017 in Brachytherapy
Verified
Journal Article
Closed access
VSVictor Srougi
Victor Srougi
EBEric Barret
Eric Barret
INIgor Nunes-Silva
Igor Nunes-Silva
MBMohammed Baghdadi
Mohammed Baghdadi
SGSilvia Garcia-Barreras
Silvia Garcia-Barreras
JCJean-Marc Cosset
Jean-Marc Cosset

28 February 2020 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
AFAndrew Fang
Andrew Fang
JRJennifer Rosen
Jennifer Rosen
ASAva Saidian
Ava Saidian
SBSejong Bae
Sejong Bae
FTFabio Y. Tanno
Fabio Y. Tanno
Soroush Rais-BahramiSoroush Rais-Bahrami
Soroush Rais-Bahrami